Profile data is unavailable for this security.
About the company
Daito Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture, sale, purchase and sale of active pharmaceutical ingredients and formulations (prescription drugs and over-the-counter drugs), contract manufacturing of active pharmaceutical ingredients and formulations, and sale of health foods and other products. The Company is primarily engaged in the pharmaceutical business segment. The main products are active pharmaceutical ingredients and formulations. The Company manufactures, sells, purchases and sells active pharmaceutical ingredients, which are raw materials used to manufacture pharmaceuticals, and undertakes contract manufacturing. The Company also manufactures, sells, purchases and sells formulations of prescription drugs and over-the-counter drugs, and undertakes contract manufacturing.
- Revenue in JPY (TTM)51.20bn
- Net income in JPY2.23bn
- Incorporated1942
- Employees1.07k
- LocationDaito Pharmaceutical Co Ltd326, Yoka-machiTOYAMA-SHI 939-8567JapanJPN
- Phone+81 764215665
- Fax+81 764216006
- Websitehttps://www.daitonet.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fuso Pharmaceutical Industries Ltd | 62.17bn | -4.01bn | 23.42bn | 1.34k | -- | 0.6105 | -- | 0.3767 | -469.00 | -469.00 | 7,280.21 | 4,059.08 | 0.7307 | 3.25 | 2.32 | 46,394,780.00 | -4.71 | 0.7682 | -9.76 | 1.29 | 26.39 | 26.94 | -6.44 | 1.05 | 0.8228 | 69.88 | 0.4617 | 106.29 | 9.31 | 5.25 | -338.78 | -- | 4.37 | 6.45 |
| Kubota Pharmaceutical Holdings Co Ltd | 21.34m | -676.25m | 25.04bn | 19.00 | -- | 13.81 | -- | 1,173.79 | -10.91 | -10.91 | 0.3341 | 15.72 | 0.0121 | 3.54 | 7.98 | -- | -38.41 | -44.81 | -42.10 | -49.35 | -14.68 | -- | -3,169.69 | -8,411.59 | 12.49 | -- | 0.0121 | -- | -21.53 | -10.80 | 49.26 | -- | -4.55 | -- |
| RaQualia Pharma Inc | 3.98bn | 273.12m | 25.70bn | 85.00 | 110.18 | 3.50 | 33.76 | 6.46 | 8.97 | 8.97 | 165.54 | 281.96 | 0.3947 | 4.35 | 3.04 | -- | 2.71 | 2.64 | 3.08 | 2.90 | 82.11 | 85.46 | 6.86 | 6.36 | 4.33 | 6.63 | 0.2962 | 0.00 | 28.07 | 29.16 | 155.17 | -- | -13.74 | -- |
| Renascience Inc | 106.94m | -258.99m | 26.16bn | 3.00 | -- | 10.61 | -- | 244.57 | -20.35 | -20.35 | 8.40 | 186.09 | 0.0479 | -- | 4.86 | 35,648,000.00 | -11.59 | -8.97 | -12.40 | -9.35 | 95.94 | 84.44 | -242.17 | -107.53 | -- | -- | 0.00 | -- | -31.66 | 13.00 | 143.91 | -- | -- | -- |
| Seikagaku Corp | 35.86bn | -755.00m | 43.63bn | 1.08k | -- | 0.5743 | 32.73 | 1.22 | -13.84 | -13.84 | 656.96 | 1,337.18 | 0.4328 | 2.03 | 3.92 | 33,360,930.00 | -0.9099 | 3.60 | -0.9881 | 3.96 | 40.92 | 52.56 | -2.10 | 7.94 | 4.26 | -- | 0.0049 | 55.17 | 8.73 | 6.57 | -44.46 | -- | 18.48 | 2.90 |
| Daito Pharmaceutical Co Ltd | 51.20bn | 2.23bn | 43.79bn | 1.07k | 19.55 | 0.825 | 6.61 | 0.8553 | 74.42 | 74.42 | 1,703.91 | 1,763.62 | 0.6544 | 2.16 | 2.76 | 47,716,680.00 | 2.90 | 5.12 | 3.71 | 6.67 | 17.63 | 21.75 | 4.43 | 7.35 | 1.31 | -- | 0.1739 | 24.48 | 7.99 | 2.39 | -42.09 | -13.52 | 20.45 | 14.00 |
| Innovacell Inc | -100.00bn | -100.00bn | 44.66bn | 48.00 | -- | 141.25 | -- | -- | -- | -- | -- | 7.58 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 12.78 | -- | 0.9377 | -- | -- | -- | -19.48 | -- | -- | -- |
| Fuji Pharma Co Ltd | 54.57bn | 2.33bn | 58.77bn | 1.76k | 24.73 | 1.20 | 9.34 | 1.08 | 95.46 | 95.46 | 2,233.29 | 1,959.48 | 0.5765 | 1.49 | 2.83 | 31,007,950.00 | 2.46 | 4.51 | 3.93 | 6.76 | 40.82 | 40.57 | 4.27 | 8.51 | 0.876 | 17.58 | 0.3885 | 25.98 | 12.01 | 8.87 | -51.19 | 7.55 | 8.07 | 7.94 |
| Cuorips Inc | 355.69m | -764.60m | 60.77bn | 56.00 | -- | 12.10 | -- | 170.85 | -93.30 | -93.30 | 43.60 | 607.39 | 0.0656 | 3.33 | 238.00 | 6,351,607.00 | -14.20 | -- | -14.62 | -- | 76.69 | -- | -216.57 | -- | 36.81 | -- | 0.00 | -- | 658.40 | -- | -1.92 | -- | -- | -- |
Data as of Mar 04 2026. Currency figures normalised to Daito Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
30.85%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Kaname Capital LP (Investment Management)as of 31 Jul 2025 | 3.35m | 11.13% |
| MFS International Singapore Pte Ltd.as of 31 Jan 2026 | 1.14m | 3.78% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 932.62k | 3.10% |
| Nomura Asset Management Co., Ltd.as of 05 Feb 2026 | 846.20k | 2.81% |
| Portfolia, Inc.as of 01 Apr 2024 | 821.40k | 2.73% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 794.47k | 2.64% |
| Sumitomo Mitsui DS Asset Management Co., Ltd.as of 05 Feb 2026 | 474.28k | 1.58% |
| Amova Asset Management Co., Ltd.as of 06 Feb 2026 | 360.50k | 1.20% |
| Daiwa Asset Management Co. Ltd.as of 30 Jan 2026 | 344.20k | 1.14% |
| T&D Asset Management Co., Ltd.as of 25 Apr 2025 | 221.60k | 0.74% |
More ▼
Data from 01 Apr 2024 - 29 Jan 2026Source: FactSet Research Systems Inc.
